Quizar 17.7 mg (Generic Quizartinib) – Everest Pharmaceuticals

Quizar 17.7 mg is a generic formulation of Quizartinib — a second-generation, highly selective Type II FLT3 inhibitor — manufactured by Everest Pharmaceuticals Ltd. under WHO-GMP certified conditions in Bangladesh. Each tablet contains 17.7 mg of quizartinib, the same active molecule found in Vanflyta® (Daiichi Sankyo), and is dispensed under the Named Patient Program for patients requiring an affordable, quality-assured alternative.

Quizartinib is used in combination with standard cytarabine and anthracycline induction and cytarabine consolidation chemotherapy, and subsequently as maintenance monotherapy — it is part of a multi-phase treatment regimen, not a standalone first-line therapy.

FLT3-ITD (internal tandem duplication) mutations occur in roughly a quarter of AML cases and drive a constitutively active growth signal that promotes leukaemic cell survival and proliferation. Quizartinib is a Type II FLT3 inhibitor — meaning it binds to the inactive conformation of the FLT3 receptor, blocking this aberrant signalling.

Quizar is typically started alongside intensive induction chemotherapy — this is a hospital-based treatment phase with close monitoring built in from day one.

• Pre-treatment: Baseline ECG and correction of any potassium or magnesium deficiency is mandatory before the first dose. Your care team will not start quizartinib until electrolytes are within safe range.
• Weeks 1–2: Quizar is given alongside induction chemotherapy (cytarabine and anthracycline) at 35.4 mg (two 17.7 mg tablets) once daily for 2 weeks per cycle. ECG monitoring continues throughout.
• Following cycles: Consolidation cycles follow a similar pattern. After achieving remission, treatment may transition to maintenance monotherapy at a lower dose (26.5 mg once daily), continuing long-term with ongoing cardiac monitoring.

Cardiac monitoring is the defining safety requirement for quizartinib — this is not optional supportive care, it is a mandatory part of the treatment protocol.

Induction/consolidation dose: 35.4 mg (two 17.7 mg tablets) once daily for 2 weeks per cycle. Maintenance dose: 26.5 mg once daily. Dosage adjustments are made strictly based on ECG/QT interval readings — always follow your oncologist’s exact protocol.

• 1
  Once daily, same time each day — consistency supports stable drug levels and predictable cardiac monitoring timing.
• 2
  Swallow tablets whole with water. Do not chew or crush.
• 3
  Never skip scheduled ECG monitoring — this is mandatory throughout treatment, not just at the start, due to the cardiac risk profile of this medication.
• 4
  Disclose all other medications — quizartinib has significant interactions with CYP3A4 inhibitors/inducers and other QT-prolonging drugs (certain antibiotics, antiemetics, antipsychotics).
• 5
  Storage: at 20°C to 25°C, protected from moisture and light, out of reach of children.

• ♥
  Track every scheduled ECG and blood test — cardiac monitoring is non-negotiable with this medication. Help maintain the monitoring calendar and ensure appointments are never missed.
• ♥
  Watch for cardiac warning signs — dizziness, fainting, palpitations, or irregular heartbeat require immediate medical attention. Do not wait to see if symptoms pass.
• ♥
  Maintain a complete medication list — many common drugs (certain antibiotics, antiemetics) can worsen QT prolongation risk. Share every medication, including over-the-counter products, with the care team.